Association of prolonged symptom duration with poor outcomes in lumbar spine surgery: a Michigan Spine Surgery Improvement Collaborative study.


Journal

Journal of neurosurgery. Spine
ISSN: 1547-5646
Titre abrégé: J Neurosurg Spine
Pays: United States
ID NLM: 101223545

Informations de publication

Date de publication:
01 10 2023
Historique:
received: 06 03 2023
accepted: 09 05 2023
medline: 3 10 2023
pubmed: 22 6 2023
entrez: 22 6 2023
Statut: epublish

Résumé

There is a scarcity of large multicenter data on how preoperative lumbar symptom duration relates to postoperative patient-reported outcomes (PROs). The objective of this study was to determine the effect of preoperative and baseline symptom duration on PROs at 90 days, 1 year, and 2 years after lumbar spine surgery. The Michigan Spine Surgery Improvement Collaborative registry was queried for all lumbar spine operations between January 1, 2017, to December 31, 2021, with a follow-up of 2 years. Patients were stratified into three subgroups based on symptom duration: < 3 months, 3 months to < 1 year, and ≥ 1 year. The primary outcomes were reaching the minimal clinically important difference (MCID) for the PROs (i.e., leg pain, Patient-Reported Outcomes Measurement Information System Physical Function (PROMIS PF), EQ-5D, North American Spine Society satisfaction, and return to work). The EQ-5D score was also analyzed as a continuous variable to calculate quality-adjusted life years. Multivariable Poisson generalized estimating equation models were used to report adjusted risk ratios, with the < 3-month cohort used as the reference. There were 37,223 patients (4670 with < 3-month duration, 9356 with 3-month to < 1-year duration, and 23,197 with ≥ 1-year duration) available for analysis. Compared with patients with a symptom duration of < 1 year, patients with a symptom duration of ≥ 1 year were significantly less likely to achieve an MCID in PROMIS PF, EQ-5D, back pain relief, and leg pain relief at 90 days, 1 year, and 2 years postoperatively. Similar trends were observed for patient satisfaction and return to work. With the EQ-5D score as a continuous variable, a symptom duration of ≥ 1 year was associated with 0.04, 0.05, and 0.03 (p < 0.001) decreases in EQ-5D score at 90 days, 1 year, and 2 years after surgery, respectively. A symptom duration of ≥ 1 year was associated with poorer outcomes on several outcome metrics. This suggests that timely referral and surgery for degenerative lumbar pathology may optimize patient outcome.

Identifiants

pubmed: 37347591
doi: 10.3171/2023.5.SPINE23249
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

452-461

Auteurs

Travis Hamilton (T)

Departments of1Neurosurgery and.

Seamus Bartlett (S)

4Wayne State University School of Medicine, Detroit, Michigan.

Nachiket Deshpande (N)

5Michigan State University College of Human Medicine, East Lansing, Michigan.

Moustafa Hadi (M)

5Michigan State University College of Human Medicine, East Lansing, Michigan.

Jared C Reese (JC)

Departments of1Neurosurgery and.

Tarek R Mansour (TR)

Departments of1Neurosurgery and.

Edvin Telemi (E)

Departments of1Neurosurgery and.

Kylie Springer (K)

2Public Health Sciences and.

Lonni Schultz (L)

2Public Health Sciences and.

David R Nerenz (DR)

3Center for Health Services Research, Henry Ford Health, Detroit, Michigan.

Muwaffak Abdulhak (M)

Departments of1Neurosurgery and.

Teck Soo (T)

6Division of Neurosurgery, Ascension Providence Hospital, Farmington Hills, Michigan.

Jason Schwalb (J)

Departments of1Neurosurgery and.

Jad G Khalil (JG)

Departments of7Orthopedics and.

Ilyas Aleem (I)

Departments of8Orthopedics and.

Richard Easton (R)

9Department of Orthopedics, Beaumont Troy Hospital, Troy, Michigan.

Miguelangelo Perez-Cruet (M)

10Neurosurgery, Beaumont Royal Oak Hospital, Royal Oak, Michigan.

Paul Park (P)

11Neurosurgery, University of Michigan, Ann Arbor, Michigan; and.

Victor Chang (V)

Departments of1Neurosurgery and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH